Session » 2023 Pediatric Rheumatology Symposium

2:30PM-3:30PM

Abstract Number: 004

Analysis of Patients with Juvenile Dermatomyositis Compared to Healthy Controls Using CITE-seq Identifies Differences in Cell Composition and Gene and Epitope Expression

2:30PM-3:30PM

Abstract Number: 003

Inflammation or Infection? Understanding Linguistic and Cultural Nuances Impacting the Care of Somali Children with Juvenile Idiopathic Arthritis

2:30PM-3:30PM

Abstract Number: 002

Re-analysis of the APPLE (Atherosclerosis Prevention in Paediatric Lupus Erythematosus) Trial Identifies Novel Determinants of Patient Heterogeneity and a Distinct Lipid Metabolomic Signature of Atherosclerosis Progression

2:30PM-3:30PM

Abstract Number: 001

Serious Infections Among Children with Systemic Lupus Erythematosus in the Pediatric Health Information System

5:10PM-5:40PM

Abstract Number: 013

Applying Pathway Analysis to Whole Genome Data to Identify Pathophysiologic Pathways in Childhood-onset Systemic Lupus Erythematosus

5:10PM-5:40PM

Abstract Number: 014

Characterizing Lupus in African American Children in Southern United States

5:10PM-5:40PM

Abstract Number: 019

Developing Standard Improvement Curves for Disease Activity, Pain and Quality of Life in Children with Newly Diagnosed Juvenile Idiopathic Arthritis: Results from the CAPRI Registry

5:10PM-5:40PM

Abstract Number: 021

Distinguishing Childhood Sjogren’s Disease in Patients Presenting with Recurrent Sialadenitis in a Multidisciplinary Clinic

5:10PM-5:40PM

Abstract Number: 023

Effect of Type 1 Interferons and JAK Inhibitors on Gene Expression in Bioengineered Pediatric Skeletal Muscle

5:10PM-5:40PM

Abstract Number: 024

Effects of Corticosteroids on Central Nervous System Microvascular Properties Assessed by Neuroimaging

5:10PM-5:40PM

Abstract Number: 015

Epigenetically-Distinct B Cell Profiles Pre- and Post-Induction Therapy in Pediatric Lupus

5:10PM-5:40PM

Abstract Number: 016

Gene Expression Changes in Polyarticular Juvenile Idiopathic Arthritis Following Tofacitinib Treatment

5:10PM-5:40PM

Abstract Number: 020

Generation of Human Resident Memory T Cells in 3D Synovial Organoid Model

5:10PM-5:40PM

Abstract Number: 022

Narrative Medicine and Pediatric Rheumatology: Addressing Burnout and Bias

5:10PM-5:40PM

Abstract Number: 025

Patient- and Center-level Risk Factors for Research Lost to Follow-up Using the Childhood Arthritis and Rheumatology Research Alliance (CARRA) Registry

5:10PM-5:40PM

Abstract Number: 017

Potential Uveitic Biomarkers in Tears of Children with Juvenile Idiopathic Arthritis: A Pilot Study

5:10PM-5:40PM

Abstract Number: 011

The Impact of Social Inequities on Presentation of Childhood-Onset Systemic Lupus Erythematosus (cSLE) at a Large Tertiary Center

5:10PM-5:40PM

Abstract Number: 012

Thrombotic Microangiopathic Changes in Kidney Biopsies of Childhood-Onset Systemic Lupus Erythematous Patients with and Without Severe Hematologic Disturbances

5:10PM-5:40PM

Abstract Number: 018

Using the Electronic Health Record to Identify Subjects with Rheumatic Disease

6:00PM-7:00PM

Abstract Number: 057

A “High-Risk” Depression/Fatigue Profile May Be Associated with Stronger Response to a Psychological Treatment for Childhood-Onset Systemic Lupus Erythematosus (cSLE)

6:00PM-7:00PM

Abstract Number: 056

An Advanced Physiotherapist Practitioner Model of Care Is Ideally Suited to Address Workforce Concerns in Pediatric Rheumatology: A Retrospective Chart Review

6:00PM-7:00PM

Abstract Number: 080

Analysis of Proteasomal Activity – a Potential Diagnostic Tool for Proteasome-associated Autoinflammatory Syndromes (PRAAS)

6:00PM-7:00PM

Abstract Number: 060

Are the Levels of Cytokines Good Biomarkers for Smoldering Disease Activity in Childhood-Takayasu Arteritis?

6:00PM-7:00PM

Abstract Number: 062

Assessment of Barriers and Facilitators in Implementation of the Childhood Arthritis and Rheumatology Research Alliance Consensus Treatment Plans

6:00PM-7:00PM

Abstract Number: 053

Can Children with Colchicine Resistant FMF Be Treated with on Demand Canakinumab Regimen?– a Multicenter Study

6:00PM-7:00PM

Abstract Number: 067

Clinical and Demographic Characteristics of Children with Anti-NMDAR Encephalitis

6:00PM-7:00PM

Abstract Number: 047

Clinical Characteristics and Outcomes of North American Youth with Lupus Nephritis Requiring Dialysis Treated with Cyclophosphamide

6:00PM-7:00PM

Abstract Number: 077

Clinical Characteristics of Chronic Recurrent Multifocal Osteomyelitis or Chronic Nonbacterial Osteomyelitis in Pediatrics; Single Center Study in Korea

6:00PM-7:00PM

Abstract Number: 074

Clinical Characteristics of Juvenile Systemic Sclerosis in Korea: A 30-year Single Center Study

6:00PM-7:00PM

Abstract Number: 071

Clinical Manifestations and Management of Takayasu Arteritis: A Single Center Pediatric Cohort

6:00PM-7:00PM

Abstract Number: 041

Cognitive Performance Score of the Pediatric Automated Neuropsychological Assessment Metrics Software in a Brazilian Cohort

6:00PM-7:00PM

Abstract Number: 046

Colchicine Adherence Among Children and Young Adults with Familial Mediterranean Fever During Treatment with interleukin-1 Inhibitors

6:00PM-7:00PM

Abstract Number: 048

Comparative Efficacy and Safety of Ibuprofen and Naproxen in the Treatment of Oligoarticular Juvenile Idiopathic Arthritis (oJIA): Bi-national Cohort Study

6:00PM-7:00PM

Abstract Number: 055

COVID-19 Vaccination in Children with Rheumatic Diseases: Results of a CARRA-wide Survey

6:00PM-7:00PM

Abstract Number: 076

COVID-Distress in Children with Systemic Lupus Erythematosus During the COVID-19 Pandemic

6:00PM-7:00PM

Abstract Number: 054

Craniofacial Localized Scleroderma: A Single Center Retrospective Cohort

6:00PM-7:00PM

Abstract Number: 087

Delays in Care, Declines in Health, and Food Insecurity in Pediatric Systemic Lupus Erythematosus Patients During the COVID-19 Pandemic

6:00PM-7:00PM

Abstract Number: 043

Development and Usability Testing of Web-based Standardized Scoring Tool for Magnetic Resonance Images from Children with Chronic Nonbacterial Osteomyelitis (CNO)

6:00PM-7:00PM

Abstract Number: 079

Dynamics of Neutrophil Activation in Repeated TLR-9-Induced Mouse Model of Macrophage Activation Syndrome

6:00PM-7:00PM

Abstract Number: 075

Emapalumab Treatment Followed by Hematopoietic Stem Cell Transplantation in Systemic Juvenile Idiopathic Arthritis Complicated by Recurrent Macrophage Activation Syndrome

6:00PM-7:00PM

Abstract Number: 052

Extreme Periodic Fever, Aphthous Stomatitis, Pharyngitis, Adenitis (PFAPA): A Discrete Group of Patients

6:00PM-7:00PM

Abstract Number: 082

Globalization and Real-World Implementation of an International Pediatric Rheumatology Learning Resource

6:00PM-7:00PM

Abstract Number: 073

Golimumab Therapy in Children with Chronic Recurrent Multifocal Osteomyelitis: A Case Series Reviewing Safety and Efficacy

6:00PM-7:00PM

Abstract Number: 058

High Levels of Psychological Distress, Depression, and Anxiety Symptoms in Children with Pediatric Rheumatologic Diseases

6:00PM-7:00PM

Abstract Number: 085

Identification of Barriers to Care Experienced by Children with Rheumatic Disease: A Qualitative Study

6:00PM-7:00PM

Abstract Number: 063

JAK Inhibition in down Syndrome Associated Arthritis (DA) – Our Experience to Date with Tofacitinib in 5 Patients

6:00PM-7:00PM

Abstract Number: 051

Juvenile Relapsing Polychondritis: A Single Center Cohort

6:00PM-7:00PM

Abstract Number: 072

Musculoskeletal Ultrasound Findings in Children with Psoriasis

6:00PM-7:00PM

Abstract Number: 069

Neutrophil-Lymphocyte and Platelet-Lymphocyte Ratios of Patients with Juvenile Systemic Lupus Erythematosus

6:00PM-7:00PM

Abstract Number: 068

Outcomes of Children with Uveitis Associated with Autosomal Dominant Neovascular Inflammatory Vitreoretinopathy (ADNIV)

6:00PM-7:00PM

Abstract Number: 045

Patient Reported Outcomes in Pediatric Vasculitis

6:00PM-7:00PM

Abstract Number: 078

Periodic Fever Syndrome and Myelodysplastic Syndrome: Possible Connections Between Two Disorders

6:00PM-7:00PM

Abstract Number: 081

Predicting Extension in Juvenile Idiopathic Arthritis

6:00PM-7:00PM

Abstract Number: 050

Predictive Value of the 2019 EULAR/ACR SLE Criteria’s Extra-Renal Domains to Renal Response One Year After Treatment in a Pediatric Lupus Nephritis Cohort

6:00PM-7:00PM

Abstract Number: 042

Prevalence of Chronic Pain in Childhood-onset Systemic Lupus Erythematosus and Juvenile Dermatomyositis

6:00PM-7:00PM

Abstract Number: 088

Quality Improvement Cycles to Actualize Distribution of the Adolescent Assessment of Preparation for Transition (ADAPT) Survey

6:00PM-7:00PM

Abstract Number: 065

Relationship Between Arthritis and Uveitis Disease Activity in Children with JIA

6:00PM-7:00PM

Abstract Number: 084

Rheum to Improve: Patient-reported Transition Readiness in a Large Pediatric Rheumatology Clinic

6:00PM-7:00PM

Abstract Number: 083

Running out of Rheum: Where Are the Pediatric Rheumatology Faculty?

6:00PM-7:00PM

Abstract Number: 086

Systemic Sclerosis Overlap Syndrome: A Case Series from a Single Large Pediatric Center

6:00PM-7:00PM

Abstract Number: 066

Telemedicine Use in the Assessment of Juvenile Myositis: A Mixed-Methods Study of an International Healthcare Provider Experience

6:00PM-7:00PM

Abstract Number: 070

The Impact of the COVID-19 Pandemic on Patients with Juvenile Idiopathic Inflammatory Myopathies

6:00PM-7:00PM

Abstract Number: 089

The Mosaic of Mental Health: Perceived Impact of a Workshop Empowering Pediatric Rheumatology Clinicians in Routine Screening and Effective Management of Mental Health Problems

6:00PM-7:00PM

Abstract Number: 064

Towards the Development of Composite Parent-Centered Disease Activity Scores for Juvenile Dermatomyositis

6:00PM-7:00PM

Abstract Number: 059

Update of Clinical and Laboratory Features of the Childhood Arthritis and Rheumatology Research Alliance (CARRA) Systemic Juvenile Idiopathic Arthritis-Associated Lung Disease (SJIA-LD) Cohort

6:00PM-7:00PM

Abstract Number: 044

Validation of Newly Proposed Classification Criteria for Pediatric Chronic Nonbacterial Osteomyelitis: A Virginia Cohort

6:00PM-7:00PM

Abstract Number: 061

Variation in Treatment Approaches to IVIG- Refractory Kawasaki Disease (KD) Among Pediatric Rheumatologists: The Childhood Arthritis and Rheumatology Research Alliance (CARRA) Treatment of Refractory KD Survey

6:00PM-7:00PM

Abstract Number: 049

What Happens After Juvenile Myositis Patients Screen Positive for Mental Health Comorbidities? Update from a Multicenter Juvenile Myositis Mental Health Screening Pilot Study

2:30PM-3:00PM

Abstract Number: 006

Implementation of Automated Depression Screening in Patients with Lupus in a Tertiary Pediatric Rheumatology Clinic

2:30PM-3:00PM

Abstract Number: 005

Real-World Application of the Pediatric Glucocorticoid Toxicity Index in Children with Lupus Nephritis: A Feasibility and Initial Validation Study

4:30PM-5:00PM

Abstract Number: 028

Achieving Medication-Free Remission in Juvenile Dermatomyositis

4:30PM-5:00PM

Abstract Number: 029

Cardiac Magnetic Resonance Imaging in Children with Systemic Lupus Erythematosus and Scleroderma Spectrum Disorders: A Single Center Experience

4:30PM-5:00PM

Abstract Number: 032

From Bedside to Bench and Back: Discovery of a Novel Missense Variant in NLRP3 Causing Atypical Cryopyrin-Associated Periodic Syndromes with Hearing Loss as the Primary Presentation, Responsive to Anti-IL1 Therapy

4:30PM-5:00PM

Abstract Number: 040

HLA DRB1*15 and Eosinophilia Are Common Among Patients with Systemic Juvenile Idiopathic Arthritis

4:30PM-5:00PM

Abstract Number: 038

HLA-DRB1*15 Alleles in Systemic Juvenile Idiopathic Arthritis with Lung Disease and Macrophage Activation Syndrome in Italy

4:30PM-5:00PM

Abstract Number: 027

Identifying and Understanding JDM in Africa: A Survey of Rheumatology Care Providers from Africa

4:30PM-5:00PM

Abstract Number: 030

International Validation of the Total Morbidity Score for Juvenile Localized Scleroderma: 2023 Update

4:30PM-5:00PM

Abstract Number: 033

Kawasaki Disease (KD) Criteria Fulfillment and Associated Outcomes in Multisystem Inflammatory Syndrome in Children (MIS-C)

4:30PM-5:00PM

Abstract Number: 031

Multisystem Inflammatory Syndrome in Children Phenotypes Vary Between SARS-CoV-2 Variants

4:30PM-5:00PM

Abstract Number: 026

Performance of the UCLA Scleroderma Clinical Trials Consortium Gastrointestinal Tract 2.0 Instrument in a Juvenile Systemic Sclerosis Cohort

4:30PM-5:00PM

Abstract Number: 036

Predictive Factors of Long-lasting Remission Following Anakinra Withdrawal in Patients with Systemic Juvenile Idiopathic Arthritis After Achievement of Clinical Inactive Disease

4:30PM-5:00PM

Abstract Number: 035

SARS-CoV-2 Vaccination of Children with a History of Multisystem Inflammatory Syndrome

4:30PM-5:00PM

Abstract Number: 034

STAT3 Gain-of-function Syndrome Mutations Are Susceptible to JAK Inhibition Despite a Spectrum of Potency

4:30PM-5:00PM

Abstract Number: 039

Towards the Definition of Cutoff Values for Disease Activity States in Systemic JIA Using the Systemic Juvenile Arthritis Disease Activity Score

4:30PM-5:00PM

Abstract Number: 037

Transcriptional Analysis of CD14+ Monocytes During Macrophage Activation Syndrome Highlights Role for Interferons and RNA Sensing in Monocytes

5:00PM-6:00PM

Abstract Number: 117

A Descriptive Study of Patients with Multisystem Inflammatory Syndrome in Children

5:00PM-6:00PM

Abstract Number: 091

Achieving Remission in Childhood-onset Systemic Lupus Erythematosus: Rapid Implementation of an EMR-integrated Dashboard to Measure Disease Activity and Remission Rates

5:00PM-6:00PM

Abstract Number: 112

Adverse Childhood Experiences: Prevalence and Relationship to Disease in Childhood-onset Lupus

5:00PM-6:00PM

Abstract Number: 133

An Interdisciplinary Team Approach to Implementation of a Social Determinants of Health Screener for Pediatric Rheumatology Patients

5:00PM-6:00PM

Abstract Number: 135

Assessing Medication Adherence in JIA: Pilot Phase Results from a Single-Center Quality Improvement Initiative

5:00PM-6:00PM

Abstract Number: 105

Awareness of Multisystem Inflammatory Syndrome in Children Among U.S. Parents: A Cross-Sectional Survey

5:00PM-6:00PM

Abstract Number: 106

Caregivers’ Perspectives on Barriers to Care in Juvenile Localized and Systemic Scleroderma

5:00PM-6:00PM

Abstract Number: 098

Characterization of Pulmonary Nodules in Juvenile-onset Systemic Sclerosis: A Single Center Case-Series

5:00PM-6:00PM

Abstract Number: 116

Clinical Significance of Anti-Scl-70 Antibodies in Pediatric Lupus Patients: A Single Center Cohort

5:00PM-6:00PM

Abstract Number: 114

Clinical Significance of SSA and SSB Antibodies in Pediatric SLE Patients: A Single Center Cohort

5:00PM-6:00PM

Abstract Number: 103

Clinical, Serologic, and Imaging Findings of Rhupus Syndrome in the Pediatric Population: A Systematic Literature Review

5:00PM-6:00PM

Abstract Number: 093

Comparison Between Induction with Rituximab and Cyclophosphamide in Treatment of Childhood-Onset ANCA-Associated Vasculitis

5:00PM-6:00PM

Abstract Number: 096

DADA2 – a Case Series from North India

5:00PM-6:00PM

Abstract Number: 115

Development of an Electronic Clinical Phenotype to Identify Potential Study Subjects with Juvenile Arthritis

5:00PM-6:00PM

Abstract Number: 108

Development of Mental Health Guidance Statements for Pediatric Rheumatology

5:00PM-6:00PM

Abstract Number: 123

Development of Specific Classification Criteria for Juvenile System Sclerosis Patients: A Scoping Review

5:00PM-6:00PM

Abstract Number: 101

Differences in Clinical and Patient-reported Outcomes in Juvenile Dermatomyositis by Race and Ethnicity

5:00PM-6:00PM

Abstract Number: 126

Facilitating Peer-to-Peer Conversations Around Key Clinical Trial Recruitment Barriers in the Limit-JIA Trial Using Low-Fidelity Video Capture

5:00PM-6:00PM

Abstract Number: 137

Geographic Mapping of Adolescents with Rheumatic Disease: Racial and Ethnic Diversity by Texas County

5:00PM-6:00PM

Abstract Number: 131

Improving Methotrexate Documentation in Electronic Health Records – a Quality Improvement Initiative

5:00PM-6:00PM

Abstract Number: 136

Incidence and Disease Burden of Juvenile Idiopathic Arthritis and Rheumatoid Arthritis After Non-Pharmaceutical Interventions in the COVID-19 Era: A Nationwide Observational Study in Korea

5:00PM-6:00PM

Abstract Number: 129

Interrogation of STAT3 Activation in Patients with Polyarticular Juvenile Arthritis (polyJIA)

5:00PM-6:00PM

Abstract Number: 124

JIA-Associated TMJ Arthritis, Idiopathic Condylar Resorption or Anterior Disc Displacement – a Care Provider Survey

5:00PM-6:00PM

Abstract Number: 122

Juvenile Arthritis in Minnesota: Geospatial Variability and Environmental Exposures in Juvenile Idiopathic Arthritis

5:00PM-6:00PM

Abstract Number: 119

Laser Flare Photometery in the Pediatric Rheumatology Clinic as a Screening Tool for Juvenile Idiopathic Arthritis Associated Uveitis

5:00PM-6:00PM

Abstract Number: 130

Levels of Neutrophil Extracellular Traps Correlate with Disease Activity in Pediatric Lupus

5:00PM-6:00PM

Abstract Number: 109

Long-term Safety of Biologics versus Conventional Synthetic Treatments in Systemic Juvenile Idiopathic Arthritis Patients

5:00PM-6:00PM

Abstract Number: 125

Measurable Outcomes of an Ophthalmology and Rheumatology Coordinated Care Clinic

5:00PM-6:00PM

Abstract Number: 110

Medications Affect Antibody Responses to COVID-19 Vaccinations in Children with Autoimmune Diseases

5:00PM-6:00PM

Abstract Number: 111

Monitoring for Hypogammaglobulinemia After B-Cell Therapy in an Academic Pediatric Center

5:00PM-6:00PM

Abstract Number: 128

Multisystem Inflammatory Syndrome in Children and Systemic Juvenile Idiopathic Arthritis Share Clinical Phenotypes and Genetic Contributions

5:00PM-6:00PM

Abstract Number: 134

Patient-Provider Communication in Pediatric Rheumatology

5:00PM-6:00PM

Abstract Number: 102

Preliminary Results from a Survey of Psychological Resilience Among JIA Patients

5:00PM-6:00PM

Abstract Number: 104

Prevalence of Celiac Disease Among Children and Adolescents with Systemic Lupus Erythematosus (SLE)

5:00PM-6:00PM

Abstract Number: 092

Procalcitonin Levels in Patients with Juvenile Dermatomyositis Compared to Healthy Controls

5:00PM-6:00PM

Abstract Number: 113

Proportion of Patients with a Polyphasic Disease Course in Systemic-onset Juvenile Idiopathic Arthritis May Be Higher in the Age of Cytokine Inhibitors

5:00PM-6:00PM

Abstract Number: 094

Provider Assessment of the Temporomandibular Joint in Juvenile Idiopathic Arthritis

5:00PM-6:00PM

Abstract Number: 132

Quality Improvement Lessons in a New Practice

5:00PM-6:00PM

Abstract Number: 090

Safety Outcomes of Combined Biologics Use in Pediatric Rheumatology: A Single Center Experience

5:00PM-6:00PM

Abstract Number: 118

Serum Hepatocyte Growth Factor in Children with Juvenile Idiopathic Arthritis

5:00PM-6:00PM

Abstract Number: 097

Survey of Covid-19 Immunization and Infection in Patients with Systemic Juvenile Idiopathic Arthritis and Adult Onset Still’s Disease

5:00PM-6:00PM

Abstract Number: 095

Systemic Juvenile Idiopathic Arthritis Associated Lung Disease in Europe

5:00PM-6:00PM

Abstract Number: 120

The Brazilian Registry of Juvenile Dermatomyositis (JDM): I- Onset Clinical Features and Disease Activity Scores by DAS-20 over 2-Years-Follow Up

5:00PM-6:00PM

Abstract Number: 100

The Brazilian Registry of Juvenile Dermatomyositis (JDM): II – A Longitudinal Assessment of Muscle Strength by Manual Muscle Test (MMT) and Childhood Myositis Assessment Scale (CMAS) Tools

5:00PM-6:00PM

Abstract Number: 121

The Effectiveness of Tonsillectomy in Periodic Fever, Aphthous Ulcer, Pharyngitis, and Adenitis Syndrome in Pediatric Patients

5:00PM-6:00PM

Abstract Number: 099

The Impact of the COVID-19 Pandemic on Juvenile Dermatomyositis

5:00PM-6:00PM

Abstract Number: 107

Validation of Serious Adverse Event Reporting in a Multicenter Registry

5:00PM-6:00PM

Abstract Number: 127

What’s in a Name? A20 Protein Expression in an in Vitro Model of A20 Haploinsufficiency

11:00AM-12:00PM

Abstract Number: 010

Remotely Delivered Psychological Intervention May Be Beneficial to Youth with Childhood-Onset Lupus: A Preliminary Investigation

11:00AM-12:00PM

Abstract Number: 007

Single Cell RNA Sequencing Analysis of the Skin to Evaluate the Effect of Autologous Stem Cell Transplant on Fibroblast Populations in Juvenile Onset Systemic Sclerosis

11:00AM-12:00PM

Abstract Number: 009

The Bridge to Adult Care from Childhood for Young Adults with Rheumatic Disease (BACC YARD) Program, a Pediatric-to-Adult Rheumatology Transition Program

11:00AM-12:00PM

Abstract Number: 008

Treatment Response and Outcomes of 63 Cases of Juvenile Dermatomyositis-Associated Calcinosis